🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

TRI Foundation's 1 of 3 organisations to secure support from 28 philanthropic trusts managed by Equity Trustees. It'll underpin TRI programs enabling researchers to establish networks, collaborate with clinicians and translate work from bench to bedside. bit.ly/4kWZrUV

Meet Mater Research Professor Jake Gratten and his team, based at TRI. They are delving into the genomic basis of conditions affecting the brain such as Parkinson’s disease, autism, multiple sclerosis and schizophrenia. Autism CRC. About Prof Gratten: bit.ly/4njODBX

TRI ACTIVATE matches researchers with industry to explore new collaborations to develop therapeutics, diagnostics and medical devices. It has tailored industry and researcher workshops and culminates in a final matched networking day. Bright Arena, bit.ly/4k4npfD

"All of the great discoveries... lie ahead of us." Welcome to TRI, UNSW Prof John Mattick and thanks for a wonderful Game Changer Seminar. Prof Mattick urged us to think differently, be curious, not dismiss anomalies in research findings. UQ News QUT Mater Research Queensland Health

"If it works, it is going to be an absolute game-changer." TRI-based John Hooper from Mater Research is one of the leaders of a first-in-human ovarian cancer study, using a "seek and destroy cancer weapon". Prof Hooper has been featured on 9News Australia. bit.ly/46kXFsd

Cellular keys to cancer survival/treatment resistance have been unlocked. Scientists including TRI-based Arutha K mapped the tissue microenvironment to identify immune cells linked to living longer with disease in remission. The work is in The The Australian. bit.ly/4lBuohx

We look forward to hearing about new ways of thinking, exploring new collaborations, bold ideas, better solutions. Hopkins Centre's Better Ideas, Bold Solutions Symposium is at TRI on Sep 2 for clinicians, researchers, service users, consumers, industry. bit.ly/44s92Mi

An RNA diagnostic for aggressive #prostate cancer is a key project QUT Prof Prof Jyotsna Batra and her team are working on at TRI. They're identifying the function of genes implicated in the cancer; new treatments; collaborating with industry. Meet Prof Batra: bit.ly/3IgCn56

“The future of precision medicine comes from taking learnings at the bench to the patient bedside and back to the bench again. This process is at the heart of translating research.” TRI CEO Prof Maher Gandhi shares his thoughts on translational research. bit.ly/4nGrJ88

Congrats, TRI-based Fernando Guimaraes from UQ News #FrazerInstUQ, joining the AusBiotech Qld Committee, providing insights in advancing biotech innovation/collaboration. He joins Kym Baker, Thermo Fisher; Samuel Jesuadian, ARM Hub; Stuart Newman, TIA. bit.ly/4lJea5U

Congrats, TRI-based Seth Cheetham from UQ News and BASE mRNA Facility, securing Australian Research Council support for work to transform how mRNA medicines are made and used. The work aims to develop a new class of mRNAs with better performance and stability, decreased cost and expanded applications.

TRI-based Rabina Giri's recognised with a Mater Research Strategic Grant for Outstanding Women. She's in the Inflammatory Bowel Disease Group with Jakob Begun. The grant will enable studies of how gut microbiota regulates signaling in colorectal cancer. bit.ly/46953XP

Congrats TRI-based Dr Joshua Tobin from Mater Research, awarded a Future Leaders Fellowship to explore how the immune system responds to cancer mutations. As a clinician-researcher, he'll use the fellowship to dedicate more time to blood cancer research. bit.ly/4nLQ9gp

"Without TRI actually taking that step to back ACCISS, none of this would have been possible." TRI is proud to have supported ACCISS, a department at that helps clinical teams better understand and solve complex medical challenges. Queensland Health bit.ly/4nD04om

Meet Nataly Stylianou and her QUT group at TRI. They’re uncovering how gene splicing and protein function drive cancer cell plasticity, a process enabling them to adapt, survive and resist treatment. They're focusing on prostate cancer and neuroblastoma. bit.ly/4lY81Dc

Can we harness our body's ability to repair DNA damage to fight cancer? At TRI, Mater Research Prof Kum Kum Khanna & her team are doing just that, translating decades of research into potential new treatments: more effective and less toxic for breast/ovarian/endometrial cancers.

It's almost time to ACTIVATE. Our biomedical activator program has workshops for industry to define innovation priorities/opportunities, and researchers to identify their value proposition. It ends with matched face to face researcher-company meetings. bit.ly/3TPlJvY

We're about to reveal our cGMP manufacturing facility's new name. Due to open in 2026, it'll be an Aussie first on-demand biomedical cGMP cleanroom facility for maturing companies, with investment from TRI and the Queensland Government. The announcement's coming soon. bit.ly/45cO4mi

"We want Brisbane synonymous with biomedical innovation." We're pleased to be in Forge Magazine. Read about TRI, Boggo Road Innovation Precinct, our CEO Prof Maher Gandhi, his vision for translating research, and our on-demand cGMP manufacturing facility. bit.ly/456QHVD

- Health Translation Queensland has launched its 2025–27 Action Plan, with health/research organisations working together to accelerate research translation. It includes TRI and our shareholder partners UQ News, QUT, Mater Research and Metro South Health (Queensland Health). bit.ly/4lOhYDe